Axiom Space CEO Tejpaul Bhatia: orbital data centers, space pharma, and the commercialization of the ISS era
Jun 27, 2025 with Tejpaul Bhatia
Key Points
- Axiom Space is on track to exceed $400 million in revenue by fractionalizing orbital infrastructure into compute nodes, labs, and manufacturing platforms sized for 70 to 100 annual astronaut missions, mirroring the hyperscaler playbook.
- Astronaut traffic to the ISS has quadrupled in four years, with Axiom's four missions accounting for 16 of those flights across 12 nations, validating demand that already outstrips available supply.
- Drugs tested on Axiom's missions have advanced to FDA-approved human trials, while the company operates the exclusive NASA contract for ISS commercial modules and supplies spacesuits for the Artemis program.
Summary
Tejpaul Bhatia, 60 days into his role as CEO of Axiom Space, is positioning the company as the foundational infrastructure layer for commercial space — an operating system, in his framing, for countries, corporations, and civilization. He joined after investing in Axiom's Series A while at Google, where he ran business lines generating over $1 billion in ARR, and spent four years traveling the world to build sovereign demand before taking the top job.
The Commercial Opportunity
Bhatia identifies three markets he believes will each reach trillion-dollar scale this decade: orbital data centers, space pharmaceuticals, and advanced materials manufacturing. The framing is explicitly analogous to 1995, with the ISS playing the role of DARPA-era infrastructure and the commercial transition mirroring the shift from proprietary servers to cloud.
Axiom has been running compute workloads with Amazon AWS since its first mission, AX1 in 2022, when the company sent up an AWS computer and began generating revenue from bits rather than atoms. Two orbital data center nodes are scheduled to launch next quarter, forming what Axiom calls a heterogeneous network, nodes with different specializations tied together by shared data architecture. The company has also sent an Alexa unit to orbit and is partnering with Oura to stream astronaut biometric data to its cloud infrastructure in space.
On pharmaceuticals, drugs tested during the Axiom 3 and Axiom 4 missions have progressed to FDA-approved human clinical trials on Earth, representing the first commercial translation of decades of microgravity research.
Business Model and Scale
Axiom's individual deals range from $50 million to $150 million, with the company on track to exceed $400 million in revenue. Bhatia is explicit that the legacy cost-per-kilogram framing is the wrong lens. The model he is building toward mirrors cloud hyperscalers: fractionalize the infrastructure, drive cost to zero or below, and offer credits to startups building applications on top, capturing value as the ecosystem scales.
Axiom holds the exclusive NASA contract to attach commercial modules to the ISS, which cost $150 billion to build and runs at roughly $5 billion per year across 15 partner nations. The company is also the sole provider of NASA spacesuits for the Artemis program — the next humans to walk on the moon will wear Axiom suits.
Astronaut Volume as the Core Thesis
Over the four years before Axiom's AX1 mission, humanity sent roughly 12 astronauts per year to orbit. That number has quadrupled in the four years since, with 16 of those additional flights attributed to Axiom across 4 missions and 12 nations, including the first Saudi female astronaut, the first Turkish astronaut, and the first citizens of India, Poland, and Hungary to reach the ISS, all on the current AX4 mission.
Bhatia's infrastructure buildout, spanning habitation modules, spacesuits, labs, and manufacturing platforms, is explicitly sized for a world where 70 to 100 people travel to orbit annually. He argues that demand at both government and corporate levels already outstrips available supply.
The 2030 Thesis
Bhatia frames 2030 as the inflection point equivalent to the Windows moment, the iPhone launch, or the release of ChatGPT for the space industry. He gives himself better than 50% odds of standing on the moon before 2050, and puts the probability of personally reaching orbit at 100%. For investors, his argument is straightforward: the question is no longer whether humans expand into space, but when, and the window to build foundational infrastructure before that inflection point is now.